Jones, A. V., Silver, R. T., Waghorn, K., Curtis, C., Kreil, S., Zoi, K., Hochhaus, A., Oscier, D. G., Metzgeroth, G., Lengfelder, E., Reiter, A., Chase, A. J. and Cross, N. C.P., 2006. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood, 107 (8), pp. 3339-3341.
Full text not available from this repository.
Official URL: http://bloodjournal.hematologylibrary.org/cgi/cont...
Imatinib and recombinant interferon alpha (rIFN) can induce remission in polycythemia vera (PV) patients, but gauging the depth of responses has not been possible due to lack of a specific disease marker. We found that patients undergoing imatinib (n = 14) or rIFN (n = 7) therapy remained strongly positive for V617F JAK2, although there was a significant reduction in the median percentage of mutant alleles that correlated with hematologic response (P = .001). Furthermore, individuals who achieved complete hematologic remission had lower levels of V617F than those who did not (P = .001). Of 9 imatinib-treated cases for whom pretreatment samples were available, 7 with no or partial hematologic responses showed a marginal increase (median, 1.2-fold; range, 1.0-1.5) in the percentage of V617F alleles on treatment, whereas the 2 patients who achieved complete hematologic remission showed a 2- to 3-fold reduction. Our data indicate that, although PV patients may benefit from imatinib or rIFN, molecular responses are relatively modest.
|Subjects:||Technology > Medicine and Health|
|Group:||School of Health and Social Care > Centre for Postgraduate Medical Research and Education|
|Deposited By:||INVALID USER|
|Deposited On:||02 Nov 2008 16:05|
|Last Modified:||07 Mar 2013 14:51|
|Repository Staff Only -|
|BU Staff Only -|
|Help Guide -||Editing Your Items in BURO|